​Invictus Provides Update on German Partnership and EU-GMP Certification

Spotlight News  |

INVICTUS MD STRATEGIES CORP.  (GENE:CA) (IVITF) ()is pleased to provide an update on its progress towards European Union Good Manufacturing Practices ("EU-GMP") certification. Invictus' wholly-owned subsidiary, Acreage Pharms Ltd. ("Acreage Pharms"), has designed and is currently building its Phase 3 and 4 purpose-built cultivation facilities to be EU-GMP compliant. EU-GMP standards are the most stringent regulations in the world and our team at Acreage Pharms are working together with professional consultants in both Canada and Germany to meet these standards.

The 90,000 square foot Phase 3 facility has an expected completion date of January 2019 and is fully funded as a result of the previously announced $25.5 million loan from ATB Financial. Approximately $10 million has been dedicated to the 90,000 square foot Phase 4 facility, which will commence construction upon completion of Phase 3.

The Invictus sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores. Our progress towards EU-GMP certification is a cornerstone for our international plan. Despite countries such as Germany, Italy, Norway, Greece, Poland, Switzerland, and the United Kingdom having implemented, or are in the process of implementing, some form of legal medical cannabis, many do not permit the cultivation of cannabis on home soil. Invictus has signed an LOI for cannabis sales into Germany and plans to supply the German market with medical cannabis upon successful receipt of its EU-GMP certification (see press release dated June 19, 2018, for further details).

The Importer, whose name will remain undisclosed until execution of a definitive Offtake Agreement, boasts a vast distribution network of 20,000 pharmacies, with a focus on product marketing and professional education. The Importer's experienced management team previously led an international joint venture successfully to the final stage of the German tender for domestic cannabis production.

For more information, please visit www.invictus-md.com.

About Invictus

Invictus is a global cannabis company offering a selection of products under a wide range of lifestyle brands. Our integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores.

Invictus has partnered with business leaders to convey our corporate vision, including KISS music legend and business mogul Gene Simmons as our Chief Evangelist Officer, and global branding agency Authentic Brands Group. Invictus is expanding its cultivation footprint, with two cannabis production facilities fully licensed under ACMPR in Canada and a third awaiting approval, featuring 100,000 square feet of available grow space today with 200,000 expected by January 2019 and 1 million by end of 2020. The Company will earmark 50 per cent of production to the medical and recreational markets, respectively. To ensure consistency in quality and supply, Invictus maintains all aspects of the growing process through its subsidiary, Future Harvest Development Ltd., a high-quality Fertilizer and Nutrients manufacturer. Invictus drives sustainable long-term shareholder value through a diversified product portfolio with over 69 Health Canada approved strains and a multifaceted distribution strategy including medical, recreational, international and retail. For more information visit www.invictus-md.com.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
IVITF Invictus MD Strategies Corp 1.32 0.03 2.37 195,865
GENE:CA Invictus MD Strategies Corp 1.70 0.02 1.19 401,535

Comments

Emerging Growth

Lexaria Bioscience Corp

Lexaria Bioscience Corp is a food sciences company. It has two distinct consumer product brands: ViPova and Lexaria Energy. It uses patent pending technology to infuse hemp oil ingredients within…